

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

The cellular response to transglutaminase-cross-linked collagen

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Chau, D., Collighan R, Verderio Edwards E, Addy V, Griffin, et al. (2005). The cellular response to transglutaminase-cross-linked collagen. *BIOMATERIALS*, 26(33), 6518-6529 [10.1016/j.biomaterials.2005.04.017].

Availability:

This version is available at: <https://hdl.handle.net/11585/671082> since: 2019-02-22

Published:

DOI: <http://doi.org/10.1016/j.biomaterials.2005.04.017>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

David Y.S. Chau, Russell J. Collighan, Elisabetta A.M. Verderio, Victoria L. Addy, Martin Griffin (2005). *The cellular response to transglutaminase-cross-linked collagen*, Biomaterials, Volume 26, Issue 33, Pages 6518-6529.

The final published version is available online at:

<https://doi.org/10.1016/j.biomaterials.2005.04.017>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

The cellular response to transglutaminase-cross-linked collagen

David Y.S. Chau^a, Russell J. Collighan^b, Elisabetta Verderio-Edwards^a, Victoria L. Addy^c,
Martin Griffin^{b,*}

^a*School of Biomedical and Natural Sciences, The Nottingham Trent University, Clifton, Nottingham, NG11 8NS, UK*

^b*School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK*

^c*BLC Leather Technology Centre Ltd., Leather Trade House, Kings Park Road, Moulton Park, Northampton, NN3 6JD, UK*

Abstract

Collagen, type I, is a highly abundant natural protein material which has been cross-linked by a variety of methods including chemical agents, physical heating and UV irradiation with the aim of enhancing its physical characteristics such as mechanical strength, thermal stability, resistance to proteolytic breakdown, thus increasing its overall biocompatibility. However, in view of the toxicity of residual cross-linking agents, or impracticability at large scales, it would be more useful if the collagen could be cross-linked by a milder, efficient and more practical means by using enzymes as biological catalysts.

We demonstrate that on treating native collagen type I (from bovine skin) with both tissue transglutaminase (TG2; tTG) and microbial transglutaminase (mTG; *Streptovorticillium mobaraense*) leads to an enhancement in cell attachment, spreading and proliferation of human osteoblasts (HOB) and human foreskin dermal fibroblasts (HFDF) when compared to culture on native collagen. The transglutaminase-treated collagen substrates also showed a greater resistance to cell-mediated endogenous protease degradation than the native collagen. In addition, the HOB cells were shown to differentiate at a faster rate than on native collagen when assessed by measurement of alkaline phosphatase activity and osteopontin expression.

Keywords: Bioactivity; Biocompatibility; Collagen; Fibroblasts; Osteoblasts; Tissue engineering

1. Introduction

Collagen is a very popular biomaterial due to its biocompatibility, i.e. the ability to support cell adhesion and proliferation. It is also biodegradable and only weakly antigenic—able to persist in the body without developing a foreign body response that could lead to its premature rejection [1]. The replacement of skin with artificial collagen–GAG matrices has been investigated since the early 1980s and is now in clinical use [2,3]. The primary reason for the usefulness of collagen in biomedical applications is that collagen can form fibres with extra strength and stability through its self-

aggregation and in vivo cross-linking [4]. Unfortunately, collagen, like many natural polymers, once extracted from its original source and then reprocessed, suffers from weak mechanical properties, thermal instability and ease of proteolytic breakdown. To overcome these problems, collagen has been cross-linked by a variety of agents—a subject of much recent research to find methods of preventing rapid absorption by the body [4]. However, these methods suffer from the problem that the residual catalysts, initiators and unreacted or partially reacted cross-linking agents used can be toxic or cause inflammatory responses if not fully removed or, simply, not cost-effective or practical at the large scale [5–7]. As a consequence, research continues to find alternative methods to stabilise collagen which are *natural*, milder, efficient and more practical.

*Corresponding author. Tel.: +44 121 204 3942; fax: +44 121 359 0578.

E-mail address: m.griffin@aston.ac.uk (M. Griffin).

Transglutaminases (EC 2.3.2.13) are a group of enzymes that can catalyse several types of post-translational modifications to proteins. The most important of these reactions results in the cross-linking of peptides or proteins to form multimers via a $\epsilon(\gamma\text{-glutamyl})\text{lysine}$ linkage using the side chains of lysine and glutamine residues. Transglutaminases are also able to covalently attach primary amine containing compounds to peptide bound glutamine, facilitating modification of the physical, chemical and biological properties of proteins [8]. For these reasons, transglutaminases have been utilised by the commercial sector in many different processes and have attracted much attention from the research community [9]. Microbial transglutaminase has been used to cross-link gelatin matrices to further increase their strength [10] and, also, to incorporate cell adhesion factors within the gel matrix, resulting in an enhancement of cell proliferation [11].

Interestingly, a novel component of the cell/tissue response to cell damage and stress is tissue transglutaminase (tTG), a Ca^{2+} -dependent mammalian form of the enzyme, which modulates cell-matrix interactions, tissue stability and a variety of other cell functions [12,13]. The entire tissue repair process is regulated by the interaction of cells with the surrounding extracellular matrix (ECM), ensuring cell adhesion, survival and proliferation [14,15]. To date, the cross-linking function of tTG in the ECM leading to ECM stabilisation/remodelling has been identified in a number of biological processes important for tissue repair [12]; in addition, at least three of the nine genes so far characterised are thought to be naturally involved in the wound healing response process [see review, 16].

The aim of this study was to investigate the use of the two different transglutaminases; the mammalian (tTG; TG2; TG-2; isolated from guinea pig liver) and the microbial enzyme (mTG; isolated from *Streptovorticillum mobaraense*) in the modification of collagen type I with the view to investigate potential application as a biocompatible natural polymer for use in soft and hard tissue repair.

2. Materials and methods

All water used was deionised using an Elgastat System 2 water purifier (ELGA Ltd., UK) and a Milli-Q water purifier (Millipore Waters, UK). All chemicals were purchased from Sigma-Aldrich, Poole, UK, unless otherwise stated. Sterile preparation of stock solutions and chemicals were performed either by filtration through a 0.22 μm Whatmann sterile filter and/or autoclaving at 121 $^{\circ}\text{C}$ at 1 bar for 1 h.

2.1. Cell culture

Human osteoblast (HOB) cells, isolated from explants of trabecular bone dissected from femoral heads following orthopaedic surgery as previously described [17] were kindly supplied by Professor S. Downes and Dr. S. Anderson (School of Biomedical Sciences, University of Nottingham) and used during this investigation. Human foreskin dermal fibroblast (HFDF) cells isolated from human neonatal foreskin were also used. Both cell lines were used during their low-passage number, ranging from 11 to 15 passages. Cell lines were cultured and maintained, in vitro, as monolayers in T-flasks using DMEM, supplemented with 10% heat-inactivated (56 $^{\circ}\text{C}$ for 1 h) FCS, 1% non-essential amino acids and 2 mM L-glutamine. Periodic additions of 1% penicillin-streptomycin were used to avoid bacterial contamination. Flasks were kept in a humidified-atmosphere incubator at 37 $^{\circ}\text{C}$ and with 5% CO_2 . Cells were routinely passaged and never allowed to reach greater than 90% confluency at any one time. For detachment, standard trypsinisation was performed using 0.25% (w/v) trypsin/2 mM EDTA solution in PBS solution.

2.2. Cell viability and proliferation

Cell counts and viability estimations were performed using the standard trypan blue exclusion technique by means of a 0.22 μm sterile filtered 0.5% (w/v) trypan blue solution and a haemocytometer. Non-viable cells stained blue due to the loss of their membrane integrity and, hence, allowed the passage of dye into the cell. Viable cells remained colourless.

Cell proliferation and viability were also measured using the CellTiter AQ One Solution Cell ProliferationTM assay kit (Promega, Southampton, UK. Cat no. G3580). Assays were performed, with reduced lighting, simply by the addition of 20 μl of CellTiter AQ reagent into the relevant samples in 100 μl of culture medium. These samples were then incubated in a humidified-atmosphere incubator at 37 $^{\circ}\text{C}$ and with 5% CO_2 for 90 min before the absorbance was read at 490 nm using a SpectraFluor[®] plate reader.

2.3. Attachment and spreading

Cells were seeded on the relevant substrate at a density of 625 cells/ mm^2 . After allowing cells to attach and spread, they were fixed in 3.7% (w/v) paraformaldehyde, permeabilised by the addition of 0.1% (v/v) Triton X-100 in PBS, before staining with May-Grunwald (0.25% (w/v) in methanol) and Giemsa stains (0.4% (w/v) in methanol, diluted 1:50 with water). Cells were then viewed at $\times 400$ magnification using an Olympus CK2 microscope. Three separate fixed-size

| | | | |
|----|---|---|-----|
| 1 | random fields per sample were photographed with an | tories, Hertfordshire, UK. Cat no. 500-0120). Fractions | 57 |
| 3 | Olympus DP10 digital camera. Pictures were analysed | containing mTG were pooled, aliquoted, freeze dried | 59 |
| 5 | using Scion Image TM software (Scion Corporation, | and stored at -70°C . Before immediate use, tTG was | 61 |
| 7 | Maryland, USA). Spread cells were distinguished and | pre-treated in 2 mM DTT in 50 mM Tris buffer (pH 7.4) | 63 |
| 9 | characterised based upon the presence of a clear halo of | for 10 min at room temperature to activate any oxidised | 65 |
| 11 | cytoplasm surrounding their nucleus as previously | enzyme, before addition to a final buffered solution | 67 |
| 13 | described [18]. | containing 5 mM CaCl_2 and, a minimum of 1 mM DTT in | 69 |
| 15 | | Tris buffer. Typical activities for the transglutaminases | 71 |
| 17 | | used in this investigation were as follows: tTG: | 73 |
| 19 | | 11500–13000 U/mg and mTG: 16000–25000 U/mg. | 75 |
| 21 | | | 77 |
| 23 | 2.4. Alkaline phosphatase (ALP) activity | | 79 |
| 25 | | 2.7. Transglutaminase activity | 81 |
| 27 | The ALP Optimized Alkaline Phosphatase EC 3.1.3.1 | | 83 |
| 29 | Colorimetric Test [®] kit (obtained from Sigma-Aldrich, | The incorporation of [^{14}C]-putrescine into N,N' - | 85 |
| 31 | Poole, UK. Cat no. DG1245-K) was used to quantify | dimethylcasein, as described previously [20], was used | 87 |
| 33 | the ALP activity. Alkaline phosphatase hydrolyses p - | to assay for TG activity and monitor the effects of the | 89 |
| 35 | nitrophenyl phosphate to p -nitrophenol and inorganic | inhibitors. Unit of transglutaminase activity is 1 nmol of | 91 |
| 37 | phosphate. The hydrolysis occurs at alkaline pH and the | putrescine incorporated per hour. | 93 |
| 39 | p -nitrophenol formed shows an absorbance maximum at | | 95 |
| 41 | 405 nm. The rate of increase in absorbance at 405 nm is | | 97 |
| 43 | directly proportional to ALP activity in the sample. | | 99 |
| 45 | Samples were treated according to the manufacturers' | | 101 |
| 47 | instructions and analysed using a Beckmann DU530 | | 103 |
| 49 | UV/Vis spectrophotometer. | | 105 |
| 51 | | 2.8. Collagen | 107 |
| 53 | 2.5. Osteopontin (OPN) concentration | | 109 |
| 55 | | Commercial calf skin collagen type I (Sigma-Aldrich, | 111 |
| | The OPN ELISA kit (obtained from CalBiochem, | Poole, UK. Cat no. C9791) was used during this | |
| | UK. Cat no. 499262) was used to quantify the | investigation. Native collagen samples were solubilised | |
| | concentration of OPN in the samples. The kit uses a | in 0.2 M acetic acid (Fisher Scientific, Loughborough, | |
| | polyclonal antibody to human OPN immobilised on a | UK. Cat no. A/0400/PB17) at 4°C with constant | |
| | micro-titre plate to bind to the human OPN. The | stirring for 24 h before use. Neutralisation of the | |
| | measured absorbance (450 nm) is directly proportional | collagen mixture was performed using a [5:3:2] ratio of | |
| | to the concentration of human OPN. Samples were | [collagen: $2 \times$ DMEM: 0.2 M NaOH buffer] respectively | |
| | treated according to the manufacturers' instructions and | to a final of pH 7.2. Tissue culture plastic was then | |
| | analysed using a SpectraFluor [®] plate reader. | covered using this collagen mix (recommended at | |
| | | 6–10 $\mu\text{g}/\text{cm}^2$) before being placed into a humidified- | |
| | 2.6. Transglutaminase | atmosphere incubator for 12 h to allow gelation to | |
| | | occur. In general, 50 μl of the collagen mix was added to | |
| | tTG was isolated and purified from guinea pig livers | each well of a 96-well plate. Plates were used within 48 h | |
| | using a combination of anion exchange, gel filtration | of the collagen matrix formation. | |
| | and affinity chromatography as previously described | | |
| | [19]. Commercial samples of TG were also used during | 2.9. Modified collagen by transglutaminase | |
| | this investigation: tTG from guinea pig liver (Sigma- | | |
| | Aldrich, Poole, UK. Cat no. T5398) and microbial | Neutralised collagen mixture was subjected to treat- | |
| | transglutaminase, mTG (Ajinomoto Corporation Inc., | ment with both tTG and mTG. Samples of the | |
| | Japan), isolated from <i>Streptovorticillium mobaraense</i> , as | neutralised collagen, as described above, were treated | |
| | the commercially available product, Activa TM WM. | with 50–1000 $\mu\text{g}/\text{ml}$ of tTG, in a reaction mix consisting | |
| | This required further purification steps to remove the | of 2 mM DTT and 5 mM CaCl_2 in 10 mM Tris buffer (pH | |
| | maltodextrin ingredient: briefly, the Activa TM WM was | 7.4). Microbial enzyme was added in 10 mM Tris buffer | |
| | dissolved in ice-cold 20 mM phosphate buffer, 2 mM | (pH 7.4). Stock solutions of: 2 mg/ml tTG and mTG, 1 M | |
| | EDTA pH 6.0 and filtered, before being loaded onto a | DTT and 1 M CaCl_2 were used to minimise total volume | |
| | 100 ml SP-Sepharose FF column overnight at a con- | changes. The enzymes were always added last to the | |
| | tinuous flow rate of 5 ml/min. The column was then | collagen-reaction mix to minimise any self-imposed | |
| | washed and proteins eluted, at the same flow rate, with a | cross-linking. Controls using 10 mM EDTA (to block | |
| | 0–1000 mM gradient of NaCl in 20 mM phosphate buffer, | tTG activity) and an active-site directed inhibitor, R281 | |
| | 2 mM EDTA pH 6.0. Fractions were assayed for protein | (a synthetic CBZ-glutaminyglycine analogue; 500 μM), | |
| | using the Bio-Rad DC protein assay (Bio-Rad Labora- | were also included in each assay. For 96-well plates, | |
| | | 50 μl of the pre-treated collagen mixture was added to | |
| | | each well before being placed into a humidified-atmo- | |
| | | sphere incubator, at 37°C and with 5% CO_2 , for 8 h. On | |

| | | |
|----|--|-----|
| 1 | removal, wells were washed twice with sterile distilled water and used immediately. | 57 |
| 3 | | 59 |
| 5 | 2.10. Determination of ϵ -(γ -glutamyl)lysine cross-link | 61 |
| 7 | Cross-linked and native samples of collagen were proteolytically digested as previously described [21] which included an initial digestion with microbial collagenase (<i>Clostridiopeptidase A</i> ; 1 mg/ml, Sigma-Aldrich, Poole, UK. Cat no. C9891) prior to the addition of further proteases. After digestion, samples were freeze dried and then resuspended in 0.1 M HCl and sonicated for 2 min to aid dispersion. An aliquot (90 μ l) was mixed with 110 μ l of loading buffer (0.2 M lithium citrate, 0.1% phenol pH 2.2) and loaded onto a Dionex DC-4A resin column 0.5 cm \times 20 cm using a Pharmacia Alpha Plus amino acid analyser. Derivatisation was performed post-column using <i>o</i> -phthaldialdehyde (0.8 M boric acid, 0.78 M potassium hydroxide, 600 mg/ml <i>o</i> -phthaldialdehyde, 0.5% (v/v) methanol, 0.75% (v/v) 2-mercaptoethanol, 0.35% (v/v) Brij 30) and the absorbance was measured at 450 nm. Dipeptide was determined by addition of known amounts of ϵ -(γ -glutamyl)lysine to the sample and comparing peak areas. | 63 |
| 11 | | 65 |
| 13 | | 67 |
| 15 | | 69 |
| 17 | | 71 |
| 19 | | 73 |
| 21 | | 75 |
| 23 | | 77 |
| 25 | | 79 |
| 27 | 2.11. Coomassie blue staining assay of cell cultures | 81 |
| 29 | The capacity of both the HOB and HFDF cells to degrade type I collagen was assessed as previously described [22]. Briefly, native and TG pre-treated collagen samples gels were plated out at 50 μ l per well of a 96-well plate. Hundred microlitres of 2×10^4 cells/ml, cultured in complete media, was then added to the wells in triplicates. Plates were then kept in a humidified-atmosphere incubator for the relevant time point(s). After incubation, cells were removed from the collagen matrix by addition of 0.5% (w/v) sodium deoxycholate in 10 mM Tris-HCl. A rinse with distilled water was performed before the collagen samples were stained with a 0.1% (w/v) Coomassie Brilliant blue stain solution (50% (v/v) methanol; 10% (v/v) acetic acid; 40% (v/v) dH ₂ O). Samples were allowed to stain for 5 min before a further rinse with distilled water. Unstained areas, which appeared lighter blue, gave an indication of collagen degradation by cells. Two separate fixed-size random fields per triplicate samples were photographed using an Olympus CK2 microscope and DP10 digital camera. | 83 |
| 31 | | 85 |
| 33 | | 87 |
| 35 | | 89 |
| 37 | | 91 |
| 39 | | 93 |
| 41 | | 95 |
| 43 | | 97 |
| 45 | | 99 |
| 47 | | 101 |
| 49 | | 103 |
| 51 | 2.12. Protein concentration | 105 |
| 53 | The total protein content of the collagen samples was determined by the Lowry method [23] using the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hertfordshire, UK. Cat no. 500-0120). | 107 |
| 55 | | 109 |
| | 2.13. Collagenase degradation of matrices following cell culture | 111 |
| | Collagen substrates were subjected to digestive treatment with 100 μ l of a 1 mg/ml microbial collagenase solution (<i>Clostridium histolyticum</i> , Sigma-Aldrich, Poole, UK. Cat no. C9891) followed by 100 μ l 0.25% (w/v) trypsin/2 mM EDTA solution in PBS solution for 24 h at 37 °C. Samples were washed twice with PBS followed by a wash with distilled water before the enzymatic digestion treatment. | |
| | 2.14. Zymography | |
| | Gelatin and collagen zymography were carried out as previously described [24] with the following adaptations: resolving gels were mixed with the following components, in order: 1 ml of 5 mg/ml of type I collagen solution (Sigma C9791) in 20 mM acetic acid (for collagen zymography)/1 ml of 5 mg/ml porcine gelatin (Sigma G2625) in H ₂ O (for gelatin zymography), 3.1 ml H ₂ O, 2.5 ml of 1.5 M Tris-HCl pH 8.8, 3.33 ml of 29% acrylamide/1% <i>N,N'</i> -methylene bisacrylamide, 50 μ l of 10% ammonium persulphate, 10 μ l of <i>N,N,N',N'</i> -tetramethylethylenediamine (TEMED). SDS was found to cause precipitation of the collagen and so was not added to the resolving gel. Stacking gels were poured in the usual way, i.e. 0.65 ml of 29% acrylamide/1% <i>N,N'</i> -methylene bisacrylamide, 3 ml H ₂ O, 1.25 ml 0.5 M Tris-HCl pH 6.8, 50 μ l of 10% SDS, 25 μ l of 10% ammonium persulphate, 5 μ l of TEMED. Samples containing matrix metalloproteinases (MMPs) were diluted 1:1 with loading buffer (1 M Tris-HCl pH 6.8, 50% glycerol, 0.4% bromophenol blue) and electrophoresed at 100 V in standard Laemmli running buffer (24 mM Tris-HCl, 192 mM glycine, 3.47 mM SDS, pH 8.3), avoiding overheating (approx. 4–5 h). After electrophoresis, gels were washed twice, with shaking, for 30 min each in 200 ml of 2.5% Triton X-100, to remove SDS and recover MMP activity. The gels were then placed in digestion buffer (100 mM Tris-HCl, 5 mM CaCl ₂ , 0.005% Brij-35, 1 μ M ZnCl ₂ , 0.001% NaN ₃ , pH 8) for 16–48 h at 37 °C. Gels were stained with 0.2% Coomassie Brilliant blue R-250 in 50% ethanol, 10% acetic acid for 2 h and destained by microwaving for 15 min (full power 850 W) in three changes of deionised H ₂ O. | |
| | 2.15. Statistical analysis of data | |
| | Differences between datasets (shown as mean \pm SD) were determined by the Student's <i>t</i> -test at a significance level of <i>p</i> < 0.05. | |

1 **3. Results**

3 *3.1. Cross-linking of collagen by microbial and tissue*
5 *transglutaminases*

7 Native collagen (type I) was treated with both tTG
9 and mTG, separately, in order to catalyse the formation
11 of ε-(γ-glutamyl)lysine cross-linking. The extent of cross-
13 linking for each of the TG treatments is shown in Table
15 1. Treatment of collagen with increasing concentrations
17 of TG led to a corresponding increase in the amount of
19 ε-(γ-glutamyl)lysine bonds present—with up to 1 mol of
21 cross-link per mole of collagen monomer. Treatment
23 with mTG gave a much greater increase (almost two-
25 fold) in the amount of isopeptide formed for the
27 equivalent protein concentration of transglutaminase
used. However, the increased specific activity of the
mTG probably accounts for the differences noted.

21 *3.2. Resistance of native and cross-linked collagen to cell-*
23 *mediated degradation*

25 Collagen treated with 50 µg/ml TG showed a greater
27 resistance to cell-mediated degradation as compared to
the native collagen, when HOB cells and HFDF were
seeded onto the collagen matrices and incubated for

57 72 h. Following removal of cells, visual comparison of
59 the Coomassie blue stained matrices and measurement
61 of the residual collagen indicated the mTG-treated
collagen to be more resistant than tTG-treated collagen
(Table 2).

63 *3.3. Matrix metalloproteinases secreted by HFDF cells*
65 *grown on transglutaminase collagen matrices*

67 Following growth on type I collagen, fibroblasts
69 showed an induction of a wide array of collagenases and
71 gelatinases when compared with growth on tissue
73 culture plastic-ware alone (Fig. 1). After growth on
75 transglutaminase cross-linked type I collagen, the
77 induction of active MMP1 (45 kDa), Fig. 1A, is much
less pronounced compared to growth on native collagen,
whereas the induction of active MMP2 (66 kDa) and
MMP9 (86 kDa), Fig. 1B, was increased particularly
when the cells were grown on collagen cross-linked by
tTG.

79 *3.4. Proliferation rates of HOB and HFDF cells on*
81 *native and TG-treated collagen substrates*

83 Proliferation rates of both HOB and HFDF cell lines
85 were enhanced on TG-treated collagen substrates with a

29 Table 1
31 Measurement of ε-(γ-glutamyl)lysine in TG-cross-linked collagen

| Sample | TG concentration (µg/ml) ^a | nmol of cross-link/mg protein sample | ± Relative change to native collagen ^b | mol cross-link/mol of collagen ^c |
|----------|--|---|--|--|
| Collagen | — | 0.16 | — | 0.02 |
| Coll-tTG | 50 | 1.09 | 6.81 | 0.13 |
| Coll-tTG | 100 | 2.40 | 15.00 | 0.29 |
| Coll-tTG | 200 | 4.60 | 28.75 | 0.55 |
| Coll-tTG | 500 | 5.40 | 33.75 | 0.65 |
| Coll-tTG | 1000 | 8.90 | 55.63 | 1.07 |
| Coll-mTG | 10 | 0.90 | 5.63 | 0.11 |
| Coll-mTG | 50 | 2.00 | 12.5 | 0.24 |
| Coll-mTG | 200 | 4.90 | 30.63 | 0.59 |
| Coll-mTG | 500 | 8.40 | 52.50 | 1.00 |

43 Cross-linking of collagen type I by different amounts of tTG and mTG after 8 h at 37 °C was undertaken as described in the Methods.

45 ^aTG activity: tTG = 11500–13000 U/mg; mTG = 16000–25000 U/mg.

^bNative collagen = 0.16 nmol cross-link.

^cM_w collagen: 120 kDa.

47 Table 2
49 Degradation of native and TG-treated collagen type I by HOB and HFDF cells

| Cell line | Collagen | Collagen-tTG (50 µg/ml) | Collagen-mTG (50 µg/ml) |
|-----------|-----------|-------------------------|-------------------------|
| HOB | 24% ± 3.1 | 55% ± 1.9 | 59% ± 2.1 |
| HFDF | 14% ± 2.6 | 30% ± 2.3 | 38% ± 2.5 |

55 After 72 h culture, cells were removed with sodium deoxycholate, residual collagen was digested with microbial collagenase and trypsin, and
solubilised protein was measured and expressed as a percentage of the initial level. Values are expressed as the mean ± SD from three independent
experiments, each with triplicate samples.




Fig. 1. Collagen (A) and gelatin (B) zymography of HFDF cell culture supernatants after 24 h growth on different media. Lane 1: molecular weight markers (BioRad 161-0317); lane 2: tTG-treated collagen; lane 3: mTG-treated collagen; lane 4: untreated collagen; lane 5: no collagen.




Fig. 2. Proliferation of HOB and HFDF cells cultured on native and TG-treated collagen substrates. HOB cells: (A) 50 µg/ml TG and (C) 100 µg/ml TG; HFDF cells: (B) 50 µg/ml TG and (D) 100 µg/ml. Proliferation rates were determined using CellTiter AQ solution. Results are the mean values \pm SD from four independent experiments, each having triplicate samples.

greater level of viability achieved throughout the 196-h culture when compared with non-cross-linked collagen (Fig. 2). In the case of HOB cells, no significant difference in number of viable cells was observed with

collagen treated with 100 µg/ml TG compared to 50 µg/ml TG. However, the HFDF cells showed an extended period of enhanced proliferation when cultured on collagen treated with 100 µg/ml TG (up to 48 h),

1 compared to 50 µg/ml TG (up to 24 h), and maintained
 3 an increase in number of viable cells until 168 h of
 5 culture.


7 **3.5. Attachment characteristics of HOB and HFDF cells**
 9 **on native and TG-treated collagen substrates**

11 Figs. 3 and 4 show the short-term cell-attachment
 13 characteristics of HOB and HFDF cells, when cultured
 15 on native and TG-treated collagen. Increased numbers
 17 of both HOB and HFDF cells attached when cultured
 19 on transglutaminase cross-linked collagen. For the HOB
 21 cells, comparable cell attachment was observed on both
 23 50 and 100 µg/ml TG-treated collagens (Fig. 4A and 4C)
 25 giving a significant increase of around ~20% in attached
 27 cells for the corresponding time points over the non-
 29 cross-linked collagen ($p < 0.05$). Comparable enhance-
 31 ments in cell attachment on the cross-linked collagens
 33 were also observed for the HFDF cells ($p < 0.05$) (Fig.
 35 4B and 4D).

57 **3.6. Spreading characteristics of HOB and HFDF cells**
 59 **on native and TG-treated collagen substrates**

61 Figs. 3 and 5 show the short-term cell-spreading
 63 characteristics of HOB and HFDF cells when cultured
 65 on native and TG-treated collagen. Increased numbers
 67 of cells spread when cultured on 50 µg/ml transglutami-
 69 nase cross-linked collagen. In the case of the HOB cells,
 71 a comparable increase of 5% in the spreading of the
 73 HOB cells, at each time point, is seen on both of the TG-
 75 treated collagens (Fig. 5A). In contrast, the HFDF cells
 77 showed significant non-spread cells on the 50 µg/ml TG-
 79 treated collagen—with increases of at least 10%
 81 observed for both of the TG-treated variants (Fig. 5B)
 83 ($p < 0.05$).

85 A further increase in the number of spread cells was
 87 also observed on cross-linked collagen using 100 µg/ml
 89 transglutaminase. In the case of HOB cells, an increase
 91 of approximately 5% can be observed in spread cells
 93 (Fig. 5C). This behaviour increased with increasing time
 95 of culture. In contrast for the HFDF cells, although
 97 there was still an increase in the spreading characteristics
 99 on the TG-treated collagen, a much more distinct and
 101



111 Fig. 3. Attachment and spreading of HOB and HFDF cells on native and TG-treated collagen type I. After 6 h incubation, cells were fixed using
 3.7% (w/v) paraformaldehyde before being stained with May-Grunwald and Giemsa stains and then viewed at $\times 400$ magnification.




Fig. 4. Attachment of HOB cells and HFDF on native and TG-treated collagen substrates. HOB cells: (A) 50 µg/ml TG and (C) 100 µg/ml TG; HFDF cells: (B) 50 µg/ml TG and (D) 100 µg/ml TG. Attachment is expressed as a percentage of the total number of attached cells after 6 h. Results are the mean values \pm SD from four independent experiments, each having triplicate samples.

significant behaviour was identified on the tTG-treated collagen with spread cells increasing by 15% for many of the time points. In contrast, the microbial-TG-treated collagen showed only a slight improvement in the spreading characteristics of cells (Fig. 5D) ($p < 0.05$).

3.7. Differentiation of HOB cells cultured on native and TG-treated collagen

Increases in ALP activity were observed in all the TG-cross-linked collagens, with the greatest increase seen with the tTG-treated collagen (Fig. 6A). A dose-dependent relationship between the concentration of TG and the increase in the ALP activity of the HOB cells ($p < 0.05$) was observed. However, with the highest concentration of mTG (250 µg/ml), there appeared to be a reduction in the corresponding amount of ALP activity when compared to tTG. In addition, higher OPN levels were observed in all the TG-cross-linked collagens—with the greatest increases seen with the 250 µg/ml concentration of transglutaminase (Fig. 6B).

This gave rise to a two-fold increase of OPN expression over non-cross-linked collagen. In summary, a dose-dependent relationship between the concentration of TG and the increase in the OPN levels of the HOB cells ($p < 0.05$) was observed.

4. Discussion

We have confirmed previous work [25], in demonstrating that treatment of collagen type I matrices with transglutaminases results in the incorporation of $\epsilon(\gamma$ -glutamyl)lysine, with both mTG and tTG introducing similar amounts of cross-link per unit activity. It has been previously demonstrated that collagen type I shows greater resistance to proteolytic degradation by matrix metalloproteinase 1 (MMP-1) in vitro after cross-linking by tTG [26]. Importantly, we have shown that collagen modified with tTG and mTG demonstrated greater resistance to the total complement of cell-secreted proteases and, as a consequence, improved resistance




Fig. 5. Spreading of HOB cells on native and TG-treated collagen substrates. Cells were cultured for 1 and 6 h as described in the Methods. HOB cells: (A) 50 μ g/ml TG and (C) 100 μ g/ml TG; HFDF cells: (B) 50 μ g/ml TG and (D) 100 μ g/ml TG. Spreading is expressed as a percentage of the total number of cells in the field of view. Results are the mean values \pm SD from four independent experiments, each having triplicate samples.

to cell-mediated degradation from cultured HOB and HFDF cells. The MMP expression profile of HFDF cells was found to alter as a result of growth on cross-linked collagen, with a reduction of active MMP-1 and a corresponding increase in active MMP-2, when compared to growth on untreated collagen. It is possible that this alteration in active MMP-1 accounts for the increased resistance of cross-linked collagen to cellular degradation. However, there is recent evidence to indicate that growth of either cultured hepatic stellate cells [27], rabbit periosteal fibroblasts [28] or human dermal fibroblasts [29] on collagen type I results in an increase in active MMP-2, which is associated with increased degradation of collagen in the matrix, independently of the collagenases [30]. In addition, changes in the mechanical characteristics of the collagen, which could be brought about by the introduction of $\epsilon(\gamma$ -glutamyl)lysine cross-link, can elicit mechano-

chemical signalling via an integrin-dependent mechanism, resulting in alterations in gene expression, thus accounting for the changes in active MMP expression observed [28,28,31]. The importance of the mechanical nature of the matrix in MMP production is exemplified by the finding that bovine aortic or human umbilical endothelial cells repress their secretion of MMP-2 entirely when subjected to shear stress for as little as 30 min [32]. Transglutaminase-cross-linked collagen may be more efficient than native collagen at inducing this response to the ECM, either through the presence of cross-links which may disturb the native conformation, or via disruption of the native fibrillar form during fibrillogenesis. Alternatively, due to the increased resistance of the cross-linked collagen to MMP degradation, fibroblasts may elicit an enhanced MMP response in a futile attempt to increase the rate of collagen breakdown.





Fig. 6. Differentiation of HOB cells cultured on native and TG-treated collagen type I. Alkaline phosphatase (A) and osteopontin levels (B) were measured as standard biochemical markers of osteoblast differentiation. Results are the mean values \pm SD from three independent experiments.

The proliferation rates and the attachment and spreading characteristics of HFDF and HOB cells were increased after growth on TG-cross-linked collagen when compared to culture on native collagen; furthermore suggesting alteration of the natural collagen conformation resulting in the exposure of cryptic cell binding sites within the cross-linked collagen [16]. Importantly, long-term growth and survival rates were also maintained. These data confirm that the cross-linked collagen is eliciting a different cellular response compared to untreated collagen. HOB cells were also found to differentiate more rapidly after culture on TG-

modified collagens as demonstrated by the corresponding increases in ALP activities and the earlier appearance of OPN. A possible explanation for this is that the TG-treated collagen matrix is in contact with the cells longer due to its increased proteolytic resistance thus providing the required integrin-mediated signal to the HOB cells necessary for differentiation [33].

The ability of tTG to act as a cell adhesion protein is well documented, promoting increased cell proliferation, spreading and attachment [34,35]. In fact, tTG, as well as Factor XIII, are critical components in the wound healing process and also in bone modelling and bone

ossification [36], where up-regulation of TG activity and enhancement of ECM cross-link formation is observed [37–41]. The cell adhesion characteristics of tTG have already been exploited to enhance the biocompatibility of medical devices [42]. Treatment of collagen type I with tTG may therefore lead to a modified collagen that is mimicking the natural remodelling/healing processes experienced in vivo. However, the finding that both the mammalian and microbial enzymes alter the biological characteristics of collagen type I in the same manner, indicates that cross-linking is essential since it is unlikely that the microbial enzyme can act as a cell adhesion protein given the large biochemical and physical differences between the enzymes [43].

5. Conclusion

In conclusion, the cellular response of HFDF and HOB cells grown on transglutaminase-cross-linked collagen is altered in such a manner that they show enhanced attachment, spreading and proliferation. Another important finding was that HOB cells differentiated faster on the cross-linked collagen. The modified collagen was also degraded at a much slower rate than native collagen further enhancing its in vivo efficacy as a biomaterial. Transglutaminases, therefore, show considerable potential as alternative cross-linking treatments for the production of novel biomaterials that do not suffer from the same drawbacks as other chemical or physical methods.

Acknowledgements

The above work has been filed as a GB patent application and supported by grant number GR/521755/01 from the EPSRC and BLC Leather Technology Centre Ltd., Northampton, UK.

References

- [1] Goo HC, Hwang YS, Choi YR, Cho HN, Suh H. Development of collagenase-resistant collagen and its interaction with adult human dermal fibroblasts. *Biomaterials* 2003;24(28):5099–113.
- [2] Bell E, Ehrlich P, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent of full thickness. *Science* 1981;221:1052.
- [3] Burke JF, Yannas IV, Quimby WC, Bondoc CC, Jung WK. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. *Ann Surg* 1981;194:413–48.
- [4] Lee CH, Singla A, Lee Y. Biomedical applications of collagen. *Int J Pharm* 2001;221(1–2):1–22.
- [5] Matsuda S, Iwata H, Se N, Ikada Y. Bioadhesion of gelatin films crosslinked with glutaraldehyde. *J Biomed Mater Res* 1999;45(1):20–7.
- [6] Ben-Slimane S, Guidoin R, Marceau D, Merhi Y, King MW, Sigot-Luizard MF. In vivo evaluation of polyester arterial grafts coated with albumin; the role and importance of cross-linking agents. *J Eur Surg Res* 1988;20:18–28.
- [7] Dunn MW, Stenzel KH, Rubin AL, Miyata T. Collagen implants in the vitreous. *Arch Ophthalmol* 1969;82:840–4.
- [8] Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. *J Biochem* 2002;368:377–96.
- [9] Collighan R, Cortez J, Griffin M. The biotechnological applications of transglutaminases. *Minerva Biotechnol* 2002;14(2):143–8.
- [10] Broderick EP, O'Halloran DM, Rotchev YA, Griffin M, Collighan RJ, Pandit AS. Enzymatic stabilisation of gelatin-based scaffolds. *J Biomed Mater Res Part B: Appl Biomater* 2004;72B(1):37–42.
- [11] Ito A, Mase A, Takizawa Y, Shinkai M, Honda H, Hata K, Ueda M, Kobayashi T. Transglutaminase-mediated gelatin matrices incorporating cell adhesion factors as a biomaterial for tissue engineering. *J Biosci Bioeng* 2003;95(2):196–9.
- [12] Aeschlimann D, Thommazy V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. *Connect Tissue Res* 2000;41:1–27.
- [13] Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. *Biochem J* 2002;368:377–96.
- [14] Sechler JL, Schwarzbauer JE. Control of cell cycle progression by fibronectin matrix architecture. *J Biol Chem* 1998;272:25533–6.
- [15] Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999;341:738–46.
- [16] Verderio E, Johnson T, Griffin M. Tissue transglutaminase in normal and abnormal wound healing: review article. *Amino Acids* 2004;4:387–404.
- [17] DiSilvio L. A novel application of two biomaterials for the delivery of growth hormone, its effects on osteoblasts. PhD thesis, University of London, UK, 1995.
- [18] Jones RA, Nicholas B, Mian S, Davies PJA, Griffin M. Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. *J Cell Sci* 1997;110:2461–72.
- [19] Leblanc A, Day N, Menard A, Keillor JW. Guinea pig liver transglutaminase: a modified purification procedure affording enzyme with superior activity in greater yield. *Protein Expression Purification* 1999;17:89–95.
- [20] Lorand L, Campbell-Wilkes LK, Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. *Anal Biochem* 1972;58:623–31.
- [21] Griffin M, Wilson J. Detection of ϵ -(γ -glutamyl)lysine. *Mol Cell Biochem* 1984;58:37–49.
- [22] Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover. *Cell* 1999;99:81–92.
- [23] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Biol Chem* 1951;193:265–75.
- [24] Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells: II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. *J Biol Chem* 1986;261(6):2814–8.
- [25] Collighan RJ, Li X, Parry J, Clara S, Griffin M. Transglutaminases as tanning agents for the leather industry. *J Am Leather Chem Assoc* 2004;99(7):293–302.
- [26] Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite JA, Haylor JL, Griffin M. Transglutaminase transcription and antigen translocation in experimental renal scarring. *J Am Soc Nephrol* 1999;10:2146–57.
- [27] Wang D, Sato M, Li L, Miura M, Kojima N, Senoo H. Stimulation of Pro-MMP-2 production and activation by native

| | | |
|----|--|----|
| 1 | form of extracellular type I collagen in cultured hepatic stellate cells. <i>Cell Struct Function</i> 2003;28:505–13. | |
| 3 | [28] Kessler D, Dethlefsen S, Haase I, Plomann M, Hirche F, Kreig T, Eckes B. Fibroblasts in mechanically stressed collagen lattices assume a 'synthetic' phenotype. <i>J Biol Chem</i> 2001;276(39):36575–85. | |
| 5 | [29] Zigrino P, Drescher C, Mauch C. Collagen-induced proMMP-2 activation by MT1-MMP in human dermal fibroblasts and the possible role of alpha2beta1 integrins. <i>Eur J Cell</i> 2001;80(1):68–77. | |
| 7 | [30] Kerkvliet EHM, Docherty AJP, Beertsen W, Everts V. Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. <i>Matrix Biol</i> 1999;18:373–80. | |
| 9 | [31] Ingber DE. Mechanobiology and diseases of mechanotransduction. <i>Ann Med</i> 2003;35(8):564–77. | |
| 11 | [32] Yamane T, Yamaguchi N, Yoshida Y, Mitsumata M. Regulation of the extracellular matrix production and degradation of endothelial cells by shear stress. <i>Int Congr Ser</i> 2004;1262:407–10. | |
| 13 | [33] Mizuno M, Fujisawa R, Kuboki Y. Type I collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-alpha2beta1 integrin interaction. <i>J Cell Physiol</i> 2000;184(2):207–13. | |
| 15 | [34] Verderio E, Nicholas B, Gross S, Griffin M. Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment and cell death. <i>Exp Cell Res</i> 1998;239:119–38. | |
| 17 | [35] Verderio E, Coombes A, Jones RA, Li X, Heath D, Downes S, Griffin M. Role of the cross-linking enzyme tissue transglutaminase in the biological recognition of synthetic biodegradable polymers. <i>J Biomed Mater Res</i> 2000;54:294–304. | 25 |
| 19 | [36] Upchurch HF, Conway E, Patterson Jr MK, Maxwell MD. Localisation of cellular transglutaminase on extracellular matrix after wounding. Characteristics of the matrix bound enzyme. <i>J Cell Physiol</i> 2001;149:375–82. | 27 |
| 21 | [37] Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. <i>Nat Rev Mol Cell Biol</i> 2003;4:40–56. | 29 |
| 23 | [38] Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. <i>Physiol Rev</i> 2003;83:835–70. | 31 |
| | [39] Davis GE, Bayless KJ, Davis MJ, Meininger GA. Regulation of tissue injury responses by the exposure of matrixcryptic sites within extracellular matrix molecules. <i>Am J Pathol</i> 2000;56:489–98. | 33 |
| | [40] Inada R, Matsuki M, Yamada K, Morishima Y, Shen SC, Kuramoto N, Yasuno H, Takahashi K, Miyachi Y, Yamanishi K. Facilitated wound healing by activation of the Transglutaminase 1 gene. <i>Am J Pathol</i> 2000;157:1875–82. | 35 |
| | [41] Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. <i>FASEB J</i> 1999;13:1787–95. | 37 |
| | [42] Heath DJ, Christian P, Griffin M. Involvement of tissue transglutaminase in the stabilisation of biomaterial/tissue interfaces important in medical devices. <i>Biomaterials</i> 2002;23:1519–26. | 39 |
| | [43] Motoki M, Okiyama A, Nonaka M, Tanaka H, Uchio R, Matsuura A, Ando H, Umeda K. Transglutaminase, US Patent No. 5156956, 1992. | 41 |
| | | 43 |
| | | 45 |